new agent (PPAR inhibitor, already in development for other diseases) for triple- bc
Research article
.
1, 1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice
Yunpeng Su , Kathryn Vanderlaag , Courtney Ireland , Janelle Ortiz , Henry Grage , Stephen Safe and Arthur Frankel
Breast Cancer Research 2007, 9:R56 doi:10.1186/bcr1761
Published 31 August 2007
Abstract (provisional)
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
Introduction
1, 1-Bis (3'-indolyl)-1-(p-biphenyl) methane (CDIM9) has been identified as a new peroxisome proliferators-activated receptor gamma (PPARgamma) agonist that exhibits both receptor dependent and independent anti-tumor activities. CDIM9 has not been previously studied against basal-like breast cancer. Our goal of this study is to investigate the anti-basal-like breast tumor activity in vitro and in vivo of CDIM9.
Methods
The effects of CDIM9 on cell protein and DNA syntheses were determined in basal-like breast cancer MDA-MB231 and BT549 cells in vitro. Maximal tolerance dose (MTD) and dose-limited toxicity (DLT) were identified in BalB/c mice and the anti-tumor growth activities were assessed in MDA-MB231 basal-like breast tumor xenografts in athymic nude mice.
Results
CDIM9 showed selective cell cytotoxicity and anti-proliferation effects on basal-like breast cancer lines. In MDA-MB231 cell, CDIM9 induced caveolin-1 and p27 expression, which was significantly down regulated by co-treatment with the PPARgamma antagonist GW9662. Non-steroidal anti-inflammatory drug-activated gene (NAG-1) and activating transcription factor 3 (ATF3) were up regulated by CDIM9 through PPAR gamma-independent pathway. CDIM9 (i.p. 40 mg/kg daily for 35 days) inhibited the growth of s.c. MDA-MB231 tumor xenografts by 87%, and produced a corresponding decrease of proliferation index. Close to half of treated mice (46%) had complete durable remissions confirmed by histology. The growth of an established tumor was inhibited by CDIM9 treatment (i.p. 64 mg/kg daily for ten days) with a mean tumor growth inhibition of 67% compared to controls. CDIM9 induced increases in tumor caveolin-1 and p27 in vivo which may contribute to its anti-tumor activity in basal-like breast cancer.
Conclusions
CDIM9 showed potent anti-proliferative effects on basal-like breast cancer cell in tissue culture and dramatic growth inhibition in animal models at safe doses. These results warrant further development of this drug for therapy of basal-like breast cancer patients.
|